The Galectin-3 levels in serum or plasma measured in our cohorts were comparable to Galectin-3 serum and plasma levels in healthy subjects measured by us and others (46, 50, 51), indicating that Galectin-3 levels are specifically increased at the primary and metastatic tumor sites. Here, LGALS3 is linked to metastatic neoplasm.